Professor Weijun Fan, head advisor of the Department of Minimally Invasive Interventional Therapy at Sun Yat-sen University Cancer Center, serves as Chief Physician and Doctoral Supervisor in the department. He currently hold the position of Chairman of the Tumor Ablation Treatment Committee under the CHINA ANTI CANCER ASSOCIATION (CACA); Chairman of the Second Term Committee on Tumor Ablation Therapy within the Chinese Society of Clinical Oncology (CSCO); Designate Chair of CSCO’s Radiological Intervention Therapy Committee; Vice Chairman of the Interventional Medicine Professional Committee of the Chinese Association of Integrative Medicine; Leader of the Tumor Ablation Technology Expert Group under the Chinese Medical Doctor Association (CMDA); Head of the Ablation Technology Expert Group at the National Health Commission’s Competency Building & Continuing Education Center; Chairman of the Guangdong Anticancer Association’s Minimally Invasive Oncology Committee; and Chief Scientist of the National Key Research and Development Program project.  

Dedicated to foundational and clinical research on solid tumor ablation for decades, Professor Fan is a leading authority and a pioneering figure in China's tumor ablation field, having established standardized training protocols for the discipline. He established the landmark ‘Three-Stage’ CMDA Tumor Ablation Training System, organized 86 specialized national training programs across China that have certified over 16,000 practitioners. As editor-in-chief, he compiled China’s first suite of standardized CMDA training textbooks—Liver Tumor Ablation Therapy, Lung Tumor Ablation Therapy, Thyroid Tumor Ablation Therapy, and Selected Cases in Microwave Ablation for Lung Tumors. And he is the editor of the first monograph—Microwave Ablation Therapy for Tumors on tumor microwave ablation in China and abroad. With over 50 peer-reviewed publications in prestigious journals, he leads multiple grants including one National Key R&D Program, three National Natural Science Foundation projects, and several provincial key initiatives. In recognition of his contributions, Professor Fan was honored with the Third ‘National Renowned Physician • Outstanding Style’ Award in 2019.  

More than fifty papers were published in core Journals in China, and more than twenty SCI papers were published on high influential SCI scientific journals, such as Journal of experimental & clinical cancer research, BMC medcine, International journal of surgery, Cancer, Advanced Materials, Hepatology, Liver international, Cancer Immunology Immunotherapy, Int Immunopharmacol, International Journal of Hyperthermia, AJR, and JVIR.

1.Tan H, Jiang Y, Shen L, Nuerhashi G, Wen C, Gu L, Wang Y, Qi H, Cao F, Huang T, Liu Y, Xie W, Deng W, Fan W. Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis. J Exp Clin Cancer Res. 2024 Dec 9;43(1):319. doi: 10.1186/s13046-024-03244-z. PMID: 39648199; PMCID: PMC11626751.
2.Shen L, Cao F, Liu Y, Nuerhashi G, Lin L, Tan H, Wen C, Wang Y, Chen S, Zou H, Xie L, Fan W. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial. BMC Med. 2025 May 9;23(1):275. doi: 10.1186/s12916-025-04110-1. PMID: 40346494; PMCID: PMC12065160.
3.Chen S, Shen L, Fan W. Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for HCC- In-depth analysis and enlightenments. Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310. Epub ahead of print. PMID: 40100369.
4.Chen S, Shen L, Lin L, Qi H, Chang B, Zeng Q, Lu L, Huang J, Tan H, Cao F, Xie L, Huang T, Wu Y, Wen C, Wang Y, Tang R, Li C, Zheng G, Nuerhashi G, Fan W. Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study. Int J Surg. 2025 Aug 7. doi: 10.1097/JS9.0000000000003138. Epub ahead of print. PMID: 40773250.
5.Zuo M, Zheng G, Cao Y, Lu H, Li D, An C, Fan W. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study. Int J Surg. 2025 Jan 1;111(1):104-112. doi: 10.1097/JS9.0000000000001940. PMID: 38995173; PMCID: PMC11745606.
6.Li X, Fan W, Zhang L, Zhao M, Huang Z, Li W, Gu Y, Gao F, Huang J, Li C, Zhang F, Wu P. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma: preliminary results. Cancer. 2011 Nov 15;117(22):5182-8. doi: 10.1002/cncr.26128. Epub 2011 Apr 26. PMID: 21523760.
7.Shen L, Jiang Y, Wu Y, Li C, Zeng Q, Lin L, Wang Y, Chen S, Cao F, Nuerhashi G, Zhang S, Zhou Z, An C, Du Z, Fan W. The Value of no Evidence of Disease (NED) in Intermediate-Stage Hepatocellular Carcinoma After TACE: A Real-World Study. Liver Int. 2025 May;45(5):e70101. doi: 10.1111/liv.70101. PMID: 40231897.
8.Chen S, Shen B, Wu Y, Shen L, Qi H, Cao F, Huang T, Tan H, Wen C, Fan W. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. Int Immunopharmacol. 2023 Jun;119:110228. doi: 10.1016/j.intimp.2023.110228. Epub 2023 Apr 28. PMID: 37121111.
9.Liu D, Cao F, Xu Z, Zhao C, Liu Z, Pang J, Liu ZX, Moghiseh M, Butler A, Liang S, Fan W, Yang J. Selective Organ-Targeting Hafnium Oxide Nanoparticles with Multienzyme-Mimetic Activities Attenuate Radiation-Induced Tissue Damage. Adv Mater. 2024 May;36(19):e2308098. doi: 10.1002/adma.202308098. Epub 2024 Jan 25. PMID: 37777858.
10.Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, Wen X, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother. 2020 Sep;69(9):1713-1724. doi: 10.1007/s00262-020-02566-z. Epub 2020 Apr 24. PMID: 32333081; PMCID: PMC7413875.
11.Shen L, Tan H, Nie J, Jiang Y, Nuerhashi G, Qi H, Cao F, Wen C, Chen S, Zhang T, Zheng W, Liu P, Liu Y, Huang T, Li D, Zhang X, Fan W. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy. Cancer Immunol Immunother. 2024 Mar 2;73(4):68. doi: 10.1007/s00262-024-03637-1. PMID: 38430269; PMCID: PMC10908608.
12.Chen S, Wu Y, Qi H, Shen L, Ma W, Cao F, Diao Y, Wang T, Ou S, Fan W. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy. Int J Hyperthermia. 2021;38(1):120-129. doi: 10.1080/02656736.2021.1876930. PMID: 33541160.
13.Chen S, Qi H, Tan H, Cao F, Xie L, Huang T, Wu Y, Wen C, Wang Y, Shen L, Fan W. Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study. J Hepatocell Carcinoma. 2025 Feb 3;12:205-218. doi: 10.2147/JHC.S505979. PMID: 39925626; PMCID: PMC11804238.
14.Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L, Fan W. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia. 2020;37(1):384-391. doi: 10.1080/02656736.2020.1752400. PMID: 32323585.

Updated by International Office, Sun Yat-sen University Cancer Center